R. Knight

发表

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Christian Jacques, Nizar Bahlis, Michele Cavo, 2014, The New England journal of medicine.

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

R. Bell, M. Kovacs, A. Lichtenstein, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases

G. Hortobagyi, R. Theriault, J. Simeone, 2000, Cancer.

A review of the history, properties, and use of the immunomodulatory compound lenalidomide

R. Chopra, J. Zeldis, R. Knight, 2011, Annals of the New York Academy of Sciences.

Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide

Ji‐Hyun Lee, W. Dalton, D. Sullivan, 2014, Leukemia & lymphoma.

Evaluation of Pharmacokinetic and Pharmacodynamic Interactions when Lenalidomide is Co-administered with Warfarin in a Randomized Clinical Trial Setting

S. Zhou, M. Palmisano, R. Knight, 2015, Clinical Drug Investigation.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, F. Awan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma.

J. Zeldis, J. Bladé, S. Rajkumar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Manish R. Patel, I. Flinn, R. Collins, 2015 .

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.

T. Choueiri, G. Srkalović, J. Zeldis, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

G. Hortobagyi, R. Theriault, H. Wheeler, 1996, The New England journal of medicine.

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

G. Hortobagyi, R. Theriault, H. Wheeler, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

G. Hortobagyi, R. Theriault, J. Simeone, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide

Ji‐Hyun Lee, W. Dalton, J. Lancet, 2016, Cancer medicine.

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

B. Skikne, J. Bennett, S. Nimer, 2013, Leukemia.

Phase 2 study of lenalidomide in transfusion-dependent , low-risk , and intermediate-1 – risk myelodysplastic syndromes with karyotypes other than deletion 5 q

J. Reeves, H. Deeg, P. Greenberg, 2007 .

Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer

R. Amato, L. M. Glodé, R. Knight, 2011, Cancers.

Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study

P. Greenberg, J. Bennett, G. Dewald, 2005 .

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

R. Foà, M. Boccadoro, G. Rossi, 2006 .

Results of a multicenter, randomized, double‐blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma

P. Hersey, M. Millward, A. Hamilton, 2009, Cancer.

Markers of bone resorption in patients treated with pamidronate.

G. Hortobagyi, R. Theriault, V. Chinchilli, 1998, European journal of cancer.

Markers of bone resorption in patients treated with pamidronate

G. Hortobagyi, R. Theriault, L. Demers, 1995 .

Sotatercept in patients with osteolytic lesions of multiple myeloma

S. Srinivasan, E. Terpos, M. Sherman, 2014, British journal of haematology.

HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery

Kimberly R. Jordan, A. Moody, R. Schulick, 2020, Journal for ImmunoTherapy of Cancer.

Safety a nd E fficacy o f B isphosphonates B eyond 2 4 M onths in C ancer P atients

G. Hortobagyi, A. Lipton, R. Knight, 2001 .

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

I. Flinn, R. Collins, P. Vyas, 2017, Blood.

Lenalidomide and venous thrombosis in multiple myeloma.

J. Zeldis, R. Knight, R. Delap, 2006, The New England journal of medicine.

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma

M. Dimopoulos, S. Lonial, R. Foà, 2012, International Journal of Hematology.

Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis

O. Laskin, R. Knight, N. Chen, 2007, Journal of clinical pharmacology.

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

S. Jagannath, S. Singhal, P. Richardson, 2005 .

ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis.

Yijun Yang, N. Borgstein, M. Sherman, 2009 .

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.

J. Maciejewski, A. Raza, M. Sekeres, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

B. Skikne, J. Bennett, S. Nimer, 2015, Leukemia.

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.

J. Zeldis, R. Knight, L. Weiss, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

P. Greenberg, J. Bennett, S. Nimer, 2006 .

Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS).

J. Maciejewski, A. Raza, M. Sekeres, 2007 .

Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

Ji‐Hyun Lee, W. Dalton, J. Lancet, 2014 .

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

H. Kreipe, A. Giagounidis, B. Schlegelberger, 2009 .

Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.

J. Bennett, H. Kreipe, A. Giagounidis, 2005 .

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2009 .

Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512).

G. Curt, R. Weiss, A. Sulkes, 1988, Cancer research.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in

D. Esseltine, S. Jagannath, A. Jakubowiak, 2012 .

Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.

R. Theriault, R. Navari, S. Madajewicz, 1994, Archives of internal medicine.

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009 .

Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function.

Michael L. Wang, M. Dimopoulos, A. Belch, 2006 .

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Michael L. Wang, J. Zeldis, T. Facon, 2006 .

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

Michael L. Wang, M. Dimopoulos, J. Zeldis, 2010, Haematologica.

Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

M. Dimopoulos, A. Chanan-Khan, A. Belch, 2006 .

Clinical predictors of response in metastatic germ cell tumors

N. Dawson, D. Mcleod, R. Knight, 1988, Cancer.

Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.

P. Fenaux, E. Hellström-Lindberg, M. Mittelman, 2010 .

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.

M. Boccadoro, A. Larocca, F. Gay, 2009, Clinical lymphoma & myeloma.

Impact of Baseline Renal Function on Transfusion-Independence Response, Survival, and Transformation to Acute Myeloid Leukemia in Patients with Deletion 5q: A Sub-Analysis of the MDS-003 Study

A. List, M. Battiwalla, R. Knight, 2008 .

The Immunomodulatory Role of Lenalidomide on Prevnar® Responses in Patients with Relapsed Multiple Myeloma: A Comprehensive Analysis of the Immune Response

C. Huff, I. Borrello, R. Knight, 2008 .

Declining Rates of Adverse Events and Dose Modifications with Lenalidomide in Combination with Dexamethasone

M. Dimopoulos, A. Shearer, D. Weber, 2008 .

Impact of Age on Transfusion Independence Response, Survival, and Transformation to Acute Myeloid Leukemia in Patients with Deletion 5q: A Sub-Analysis of the MDS-003 Study

A. List, M. Battiwalla, R. Knight, 2008 .

Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin.

J. Zeldis, D. Weber, R. Knight, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P122 Value of transfusion-free living in myelodysplastic syndromes (MDS): results of health utility interviews with patients

T. Goss, G. Mufti, M. Lübbert, 2007 .

P-121 Lenalidomide (CC-5013; revlimid™)-inducedred blood cell (RBC) transfusion-independence (TI) responses in low-/INT-1-risk patients with myelodysplastic syndromes (MDS): Results of the multicenter mds 002 study

J. Reeves, J. Bennett, G. Dewald, 2005 .

C028 Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion

J. Bennett, G. Dewald, A. List, 2007 .

Extragonadal germ cell tumors. Clinicopathologic findings and treatment experience in 12 patients

J. Waxman, N. Dawson, D. Mcleod, 1988, Cancer.

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

Sin-Ho Jung, A. Palumbo, P. Richardson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

A. Belch, J. Zeldis, D. Weber, 2006 .

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.

F. Zhan, M. Dimopoulos, L. Fink, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Michael Wang, Michael L. Wang, S. Lonial, 2007, The New England journal of medicine.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Alessandro Corso, Robin Foà, M. Dimopoulos, 2007, The New England journal of medicine.

Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

M. Kovacs, A. Lichtenstein, J. Simeone, 1996, The New England journal of medicine.

Thalidomide and its analogs for hemoglobinopathies: two birds with one stone?

P. Swerdlow, A. Kutlar, R. Knight, 2012, Expert review of hematology.

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

P. Swerdlow, A. Kutlar, R. Knight, 2013 .

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

J. Reeves, H. Deeg, P. Greenberg, 2008, Blood.

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

A. Dalgleish, P. Fields, R. Knight, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Valuation of transfusion-free living in MDS: results of health utility interviews with patients

Pierre Fenaux, Michael Lübbert, T. Goss, 2009, Health and quality of life outcomes.

Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.

T. Goss, M. Jädersten, E. Hellström-Lindberg, 2006, Cancer control : journal of the Moffitt Cancer Center.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Diane Warren, Edie Weller, S. Jagannath, 2006, Blood.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

P. Greenberg, J. Bennett, R. Stone, 2006, The New England journal of medicine.

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

M. Cazzola, A. Ganser, G. Mufti, 2011, Blood.

Enasidenib in mutant IDH 2 relapsed or refractory acute myeloid leukemia

I. Flinn, P. Vyas, K. Yen, 2017 .

Efficacy of lenalidomide in myelodysplastic syndromes.

L. Rimsza, D. Mahadevan, D. Roe, 2005, The New England journal of medicine.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010, Blood.

Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans

J. Zeldis, R. Knight, J. Hui, 2013, Proceedings of the National Academy of Sciences.

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, J. Zeldis, M. Petrucci, 2009, Leukemia.

Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response.

M. Dimopoulos, J. Zeldis, J. Harousseau, 2007 .

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.

Faith Davies, Edie Weller, Kenneth Anderson, 2004, Mayo Clinic proceedings.

Lenalidomide in multiple myeloma: current role and future directions

J. Zeldis, R. Knight, C. Jacques, 2010, Expert opinion on pharmacotherapy.

Mature results of MM‐011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma

G. Srkalović, M. Kalaycio, J. Zeldis, 2014, American journal of hematology.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

D. Esseltine, S. Jagannath, N. Munshi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolonged Overall Survival with Lenalidomide Plus Dexamethasone Compared with Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma.

M. Dimopoulos, J. Zeldis, D. Weber, 2007 .

Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

M. Dimopoulos, D. Siegel, J. Zeldis, 2011, Clinical lymphoma, myeloma & leukemia.

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

M. Dimopoulos, A. Belch, J. S. San Miguel, 2009, European journal of haematology.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Michael L. Wang, M. Dimopoulos, J. Zeldis, 2008, Blood.

A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.

J. Zeldis, J. Bladé, S. Rajkumar, 2006 .

Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy

P. Hwu, Kevin B. Kim, A. Bedikian, 2010, Melanoma research.

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.

K. O'Byrne, W. Steward, R. Sharma, 2006, European journal of cancer.

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.

R. Foà, M. Boccadoro, F. Gay, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Jerome B. Zeldis, M. Dimopoulos, J. Zeldis, 2005 .

IMiDs: a novel class of immunomodulators.

R. Knight, Robert Knight, 2005, Seminars in oncology.

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

E. Kimby, J. Gribben, F. Bosch, 2008 .

Results of a multicenter, randomized, double‐blind, dose‐evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma

M. Atkins, S. O’Day, A. Bedikian, 2009, Cancer.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

David E. Irwin, S. Jagannath, S. Singhal, 2009, Blood.

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

M. Dimopoulos, J. Cavenagh, A. Dispenzieri, 2013 .

D. Revicki, P. Fenaux, P. Muus, 2013, Leukemia research.

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

W. Jędrzejczak, S. Rajkumar, J. Zeldis, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience

M. Mateos, M. Cibeira, R. Knight, 2012, Leukemia & lymphoma.

myeloma regardless of prior thalidomide exposure dexamethasone alone in patients with relapsed or refractory multiple Lenalidomide plus dexamethasone is more effective than

Michael L. Wang, M. Dimopoulos, J. Zeldis, 2008 .

Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

S. Jagannath, N. Munshi, P. Richardson, 2006 .

Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009).

A. Belch, J. Zeldis, D. Weber, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

P. Richardson, Shaji K. Kumar, D. Reece, 2009, British journal of haematology.

Peripheral Neuropathy In Multiple Myeloma Patients Treated with Lenalidomide

R. Knight, Zhinuan Yu, J. Freeman, 2010 .

Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis).

M. Dimopoulos, J. Miguel, J. Zeldis, 2007 .

ECOG Performance Status Affects Efficacy, but Not Safety, of Lenalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (MM009/010 Sub-Analysis).

M. Dimopoulos, J. Miguel, A. Chanan-Khan, 2007 .

Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).

Michael L. Wang, A. Chanan-Khan, A. Belch, 2006 .

Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide

J. Hardin, J. Mehta, S. Srinivasan, 2016, Leukemia & lymphoma.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010 .

Venous Thromboembolism in Myelodysplastic Syndrome Patients Receiving Lenalidomide

J. Zeldis, Xionghu Yang, R. Knight, 2009, Clinical drug investigation.

A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy.

M. Puccio, H. Raftopoulos, R. Knight, 2011, Journal of Clinical Oncology.

A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.

S. Jagannath, N. Munshi, P. Richardson, 2005 .

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Hua Yang, E. Attar, S. Agresta, 2015 .

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

G. Morgan, M. Dimopoulos, M. Drayson, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function

Michael L. Wang, M. Dimopoulos, D. Weber, 2008 .

Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.

S. Trudel, D. Reece, V. Kukreti, 2006 .

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Shaji K. Kumar, D. Reece, J. Zeldis, 2006 .

Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.

S. Trudel, D. Reece, V. Kukreti, 2006 .

An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma.

R. Knight, M. Streetly, S. Rassam, 2003 .

A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy

L. Kwak, J. Zeldis, L. Fayad, 2007 .

Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML.

E. Hellström-Lindberg, H. Kreipe, A. Giagounidis, 2008 .

Pharmacokinetics of lenalidomide in subjects with various degrees of renal function

J. Zeldis, O. Laskin, R. Knight, 2007 .

Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.

D. Esseltine, K. Anderson, S. Jagannath, 2010 .

Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

S. Jagannath, S. Singhal, P. Richardson, 2008 .

Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma

S. Jagannath, P. Richardson, J. Zeldis, 2008 .

Lenalidomide/Dexamethasone Improves Response and Prolongs Time to Progression, Even in Patients with IgA Multiple Myeloma: A Sub-Analysis of the MM-009/010 Studies.

M. Dimopoulos, R. Foà, A. Chanan-Khan, 2007 .

PP-8-8 Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly pamidronate sodium (AREDIA®) infusion

R. Theriault, J. Simeone, S. Glück, 1996 .

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Michael L. Wang, J. Zeldis, D. Weber, 2008 .

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

R. Collins, H. Kantarjian, M. Tallman, 2016 .

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, F. Awan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

G. Morgan, M. Dimopoulos, M. Drayson, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

D. Revicki, P. Fenaux, P. Muus, 2013, Leukemia research.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael L. Wang, A. Younes, J. Zeldis, 2008 .

Preliminary analysis of a phase 1/2 study of NEXI-001 donor-derived multi-antigen-specific CD8+ T-cells for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT).

M. Perales, V. Edavana, R. Knight, 2021 .

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

Sin-Ho Jung, A. Palumbo, P. Richardson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2009 .

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

G. Srkalović, J. Zeldis, G. Pearce, 2004 .

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Michael L. Wang, M. Dimopoulos, S. Rajkumar, 2008, Blood.

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

N. Zhang, G. Kaufmann, J. Zeldis, 2019, Blood.

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

N. Zhang, G. Kaufmann, J. Zeldis, 2019, Blood.

Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

M. Boccadoro, S. Bringhen, G. Rossi, 2005 .

Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience

M. Mateos, M. Cibeira, R. Knight, 2010 .

Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

M. Dimopoulos, D. Siegel, J. Miguel, 2008 .